Going Back to a New Approach: FDA, Outside Experts, and Conflicts of Interest
This article was originally published in RPM Report
Executive Summary
FDA has gone far-maybe too far-in excluding outside experts from advisory committee panels who have potential conflicts of interest. The agency is considering easing back the restrictions. What will it mean for future external guidance to FDA?